PAVmed Inc.
News
PAVmed (NASDAQ:PAVM) Price Target Lowered to $21.00 at Ascendiant Capital Markets
Ticker Report PAVmed (NASDAQ:PAVM - Get Free Report) had its target price dropped by equities research analysts at Ascendiant Capital Markets from $22.00 to $21.00 in a report released on Tuesday, Marketbeat.com...\n more…
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
PR Newswire Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress Lucid Diagnostics to Host...\n more…
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
PR Newswire Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health PR Newswire NEW YORK, Sept. 3, 2024...\n more…
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer
PR Newswire Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer Lucid Diagnostics Announces Publication of Analytical...\n more…
Equities Analysts Offer Predictions for PAVmed Inc.'s FY2024 Earnings (NASDAQ:PAVM)
Ticker Report PAVmed Inc. (NASDAQ:PAVM - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for PAVmed in a report released on Wednesday, August 14th...\n more…